Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Commercialization Timeline Change
View:
Post by Eoganacht on Feb 17, 2022 5:06pm

Commercialization Timeline Change

In the Sep 2021 Corporate Presentation, on the Phase II Timeline page, commercialization is set to begin in mid-2025 and there is a note - Partner with Big Pharma To Commercialize.

In the Feb 7 2022 Corporate Presentation, on the Phase II Timeline page, commercialization is set to begin in January 2023 (11 months from now) and there is no mention of partnering with big pharma.

What has changed in the last 5 months?
Comment by StevenBirch on Feb 17, 2022 5:08pm
Nice catch.
Comment by enriquesuave on Feb 17, 2022 5:09pm
No partnership,so maybe a Buyout instead?  Who knows, or just an oversight?  
Comment by gebremeskel on Feb 17, 2022 5:19pm
Maybe leaving out mention of a partnership was an oversight, but how could we be granted accelerated approval by January 2023? Could there have been a communication from the FDA we haven't heard about yet?
Comment by CancerSlayer on Feb 17, 2022 6:26pm
  Thanks Eoganacht...I think the latest presentation timeline simply better represents TLT's stance.  Their latest projected commercialization timeline is Jan 2023 to Dec 2025.  Jan 2023 is oddly fast...even a Big Pharma partner or buyout wouldn't expedite this trial to that degree imo.  To me, it may simply mean FDA guidance could be allowing earlier ...more  
Comment by CancerSlayer on Feb 17, 2022 7:22pm
Or, & more likely....the "commercialization phase" timeline (starting early 2023) may simply represent business planning/strategizing for a future commercial roll-out (I.e. feasibility, costs, price point, etc.) prior to actual market approval (projected to be mid-end of 2025).
Comment by O12009 on Feb 17, 2022 8:31pm
  In the past when we find out new information we always go back to prior news releases and there it is spelled out. So I don't think it's a mistake when they say January 2023 and they leave out that's with a partner. This should make for a fantastic news release. 
Comment by CancerSlayer on Feb 17, 2022 9:58pm
  I wouldn't mind catching that Big Fish in the upstream as long as it spawns plenty of commercial & shareholder success in the downstream.  Expecting good news, but I'll take fantastic.  Good luck.
Comment by 99942Apophis on Feb 17, 2022 10:14pm
Hey guys this coming Monday February 21 puts us into the beginning time frame where the Newsletter "might" be released! Please keep in mind the time frame extends through to the week of March 7 and the Friday of that week being March 11.  Are we  there?  Yes we are almost there!
Comment by Legit62 on Feb 18, 2022 8:47am
would tend to agree we are really close, would be nice monday but march is almost here, also if they state commercialization early 2023 i think would ease the minds and we head up fast
Comment by floatinketucky on Feb 17, 2022 5:24pm
So a 3 year step forward of commercializion timline...   Now do ya'll recall that lil ol pr about the little fda darling being on the phone to daddy FDA. FDA was like little darling you just call me right up if you want to talk... Looks like they been chattin it up.
Comment by floatinketucky on Feb 17, 2022 5:28pm
And whats changed is the stataus ot the data with each reporting.  They prolly gonna chat some more with big daddy FDA... mmmm   hhhh  mmmmmm Might be the geentle thing to do.. Somewhere is the data forward from Nov 29 .. migntheybe eyes on it now???
Comment by floatinketucky on Feb 17, 2022 6:11pm
As a Fast Track designee, Theralase® will have access to early and frequent communications with the FDA to discuss Theralase’s development plans and ensure timely collection of the appropriate clinical data to support the approval process.
Comment by skys1 on Feb 18, 2022 2:00pm
What has changed in the last 5 months? Dr. Vera. That was pre Dr Vera. Post 10/21 or post Dr Vera's arrival, Company opinions and forward guidance will substantially influenced by Dr Vera's vast experience.
Comment by fredgoodwinson on Feb 18, 2022 2:21pm
Yes skys1 - Vera`s appointment was transformational for the Company and her willingness to join a huge endorsement of Theralases`s tech.
Comment by skys1 on Feb 18, 2022 2:55pm
Agree Fred, Now with Dr Vera at the trial helm, TLT is a very different company, and I might add, a substantially better company that knows where it is going, and how to get there.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250